Background/Aims: Few studies have investigated hepatitis A virus (HAV) seroepidemiology in Koreans with chronic liver disease (CLD). This study compared the prevalence of IgG anti-HAV between the general healthy population and patients with hepatitis B virus-related CLD (HBV-CLD), with the aim of identifying predictors of HAV prior exposure. Methods: In total, 1,319 patients were recruited between June 2008 and April 2010. All patients were tested for IgG anti-HAV, hepatitis B surface antigen (HBsAg), and antibodies to hepatitis C virus. The patients were divided into the general healthy population group and the HBV-CLD group based on the presence of HBsAg. The seroprevalence of IgG anti-HAV was compared between these two groups. Results: The age-standardized seroprevalence rates of IgG anti-HAV in the general healthy population and patients with HBV-CLD were 52.5% and 49.1%, respectively. The age-stratified IgG anti-HAV seroprevalence rates for ages ≤19, 20-29, 30-39, 40-49, 50-59, and ≥60 years were 14.3%, 11.2%, 45.5%, 90.5%, 97.6% and 98.3%, respectively, in the general healthy population, and 0%, 9.8%, 46.3%, 91.1%, 97.7%, and 100% in the HBV-CLD group. In multivariate analysis, age (<30 vs. 30-59 years: OR=19.339, 95% CI=12.504-29.911, P<0.001; <30 vs. ≥60 years: OR=1060.5, 95% CI=142.233-7907.964, P<0.001) and advanced status of HBV-CLD (OR=19.180, 95% CI=4.550-80.856, P<0.001) were independent predictors of HAV prior exposure. Conclusions: The seroprevalence of IgG anti-HAV did not differ significantly between the general-healthy-population and HBV-CLD groups. An HAV vaccination strategy might be warranted in people younger than 35 years, especially in patients with HBV-CLD. (Korean J Hepatol 2010;16:362-368) 
INTRODUCTION
Hepatitis A is usually self-limited and has a benign clinical course. It is usually asymptomatic in children, whereas it causes clinically apparent disease in the majority of adults, rarely progressing to fulminant hepatic failure. 1 In particular, the old age and chronic liver disease (CLD) have been known to be risk factors for fulminant hepatic failure. 2 Therefore, hepatitis A virus (HAV) vaccination is recommended for patients with CLD.
Improvements in the socioeconomic status and general public health of Korea have led to a shift in the seroprevalence of hepatitis A from hyperendemic region to lower one. 3 Paradoxically, the number of children and young adults who are susceptible to HAV infection has been gradually increased, resulting in the recent rapid rise of symptomatic hepatitis A. Currently, hepatitis A has become one of the most common causes of acute viral infection in Korean adults. 3, 4 Although the prevalence of chronic hepatitis B virus (HBV) infection has been declined after the introduction of universal vaccination, it is still the most important cause of CLD in Korea. 5 Accordingly, the seroprevalence of hepatitis A in patients with HBV-related CLD has been of interest.
PATIENTS AND METHODS

Patients and study design
We retrospectively analyzed the medical records of 1,319 pa- The severity of liver disease was classified as follows: 1) inactive HBsAg carrier was defined as those who were positive to HBsAg for more than six months, were negative to hepatitis B e antigen, had a serum level of HBV DNA<10 4 copies/mL and persistently had normal levels of serum ALT for more than one year, 2) chronic hepatitis B (CHB) patient was defined as those who had a serum level of HBV DNA >10 4 copies/mL, had serum ALT level elevated persistently or intermittently and had a lack of evidences demonstrating the presence of liver cirrhosis and hepatocellular carcinoma, 8 3) liver cirrhosis was diagnosed by histology or ultrasonographic/CT imaging features, supplemented with clinically relevant portal hypertension (esophageal and/or gastric varices, ascites, splenomegaly with a platelet count of<100,000/mm 3 ) or hepatic encephalopathy, 4) hepatocellular carcinoma was made according to the guidelines of American Society for the Study of Liver Diseases, which was based on the imaging study and serum alpha-fetoprotein levels. 9 The current study was conducted in compliance with the dec- 
RESULTS
Baseline characteristics of the patients
The number of general healthy population and that of patients with HBV-related CLD were 622 and 697, respectively. Mean (281/622) and 64.6% (450/697), respectively. There were significant differences in age and sex between the two groups (P<0.001). Of patients with HBV-related CLD, a total of 14 patients had a superinfection with chronic hepatitis C ( Table 1) .
Comparison of the seroprevalence of IgG anti-HAV between general healthy population and patients with HBV-related CLD 4 These results indicate that the incidence of acute hepatitis A occurred at an incidence of almost 30 cases per 100,000 Korean people, which urges to promote HAV vaccination for childhood and high risk groups.
The superinfection of hepatitis virus infection in patients with
CLD may aggravate the underlying liver disease. Korea is an endemic area of HBV infection. 11 and superinfection with HAV in HBV-related CLD remains problematic in these days. In Thai, it has been reported that the incidence and mortality of fulminant hepatic failure were 55% and 25% in cases of acute hepatitis A superinfection in HBsAg carriers. 12 Chu et al. from Taiwan reported that risks of developing fulminant hepatic failure were approximately nine times higher in HBsAg carriers than noncarriers. 13 According to a study about the prevalence of hepatitis A, which was conducted in Shanghai and the USA, Keeffe reported that the mortality was approximately 6-58 times higher in HBsAg-positive patients as compared with HBsAg-negative patients. 14 In a Korean study, 15 it was demonstrated that HBV-related CLD is related to the poor prognosis of acute hepatitis. As mentioned above, considering the marked increase analysis. Also in Korea, Cho et al. 18 also reported that the age was the independent factor affecting HAV prior exposure, which was consistent with our findings.
In respect to the positive rate for IgG anti-HAV, our study
showed similar results to other Korean reports (Table 3) . 6, 7, [19] [20] [21] [22] [23] [24] [25] [26] The positive rate for IgG anti-HAV was found to be higher than 90% in patients aged 45 years or older. Most of these patients were exposed to HAV previously and then spontaneously acquired an immunity against hepatitis A. In patients aged 29 years or younger, the positive rate for IgG anti-HAV was found to be lower than 15%. These results suggest that most of these patients were devoid of immunity. In patients aged between 30 and 44 years old, the positive rate for IgG anti-HAV varied ranging from 28 to 86%. These results indicate that the selective vaccination strategy would be warranted for these age groups. According to Saab et al., 27 in cases in which the positive rate for IgG anti-HAV was higher than 35%, the selective vaccination had an excellent profile of cost-effectiveness as compared with the universal vaccination. According to the current study, the prevalence of Korea. This should also be followed by a nationwide epidemiological study. Besides, the age and the severity of hepatic diseases were found to be variables affecting the HAV prior exposure, based on which the HAV vaccination strategy should be established.
